STOCKWATCH: Battle r-oil
This article was originally published in Scrip
Executive Summary
The swing in Amarin's fortunes continue, from the highs of an FDA approval to the lows of whether the drug will ever be marketed. The most recent blow to the Irish drug developer was announced on Thanksgiving Day when most of Amarin's investors were away from their offices but the acquisition of Norwegian company Pronova by BASF may be another reason why the marketing battle of prescription fish oil products in cardiovascular indications may never occur.